Spots Global Cancer Trial Database for A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
Official Title: A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
Study ID: NCT01682473
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.
Detailed Description: Open-label, uncontrolled, serial cohort, dose-escalation study evaluating two different dosing regimens (Arm 1: cycles of 5 days on drug and 2 days off drug), Arm 2: cycles of 21 days on drug and 7 days off drug).
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center Hospital East, Kashiwa-city, Chiba, Japan
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
Contact Details
Name: Toshihiko Doi, MD, PhD
Affiliation: National Cancer Center Hospital East
Role: PRINCIPAL_INVESTIGATOR
Name: Shunji Takahashi, MD
Affiliation: The Cancer Institute Hospital of JFCR
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
